ACET — ADICET BIO, INC.

Ownership history in JOHNSON & JOHNSON  ·  18 quarters on record

This page tracks every 13F SEC filing in which JOHNSON & JOHNSON reported a position in ADICET BIO, INC. (ACET). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
3.05% (2022 Q3)
Avg. % of fund
0.85%
First filed
2021 Q3
Last filed
2025 Q4
Quarters held
18
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 22,779 -341,693 -93.8% 0.03% $192K $8.42
2025 Q3 UNCHANGED 364,472 — 0% 0.06% $295K $12.96
2025 Q2 UNCHANGED 364,472 — 0% 0.07% $228K $9.76
2025 Q1 UNCHANGED 364,472 — 0% 0.08% $275K $12.08
14 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ACET price (monthly, adj. close)

Other funds also holding ACET

As of 2025 Q4 — sorted by position size

REGENERON PHARMACEUTICALS, INC. 1.51% Stonepine Capital Management, LLC 3Y 7Y 1.35% LUMINUS MANAGEMENT LLC 3Y 7Y 0.44% Prosight Management, LP 3Y 7Y 0.44% DAFNA Capital Management LLC 3Y 7Y 0.18% ORBIMED ADVISORS LLC 3Y 7Y 0.18% Rangeley Capital, LLC 0.17% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 0.08% ADAR1 Capital Management, LLC 0.08% Burkehill Global Management, LP 0.03%
← Back to JOHNSON & JOHNSON Holdings